Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin vs Standard Therapy for S. aureus Bacteremia and Endocarditis
NCT00093067Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2002
- Primary completion
- Nov 2004
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
A Phase 3 trial of daptomycin in infective endocarditis (IE), Bacteremia, sponsored by Merck & Co.. Started Mar 2002; status: completed.
02
Drugs
daptomycin
03
Conditions
infective endocarditis (IE)Bacteremia
Beyond the preview
Go deeper on NCT00093067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093067.